Tempest Therapeutics, Inc. announced the first patient has been dosed in the global randomized Phase Ib/II clinical study evaluating TPST-1120, Tempest’s small molecule PPAR⍺ antagonist, in combination with the standard-of-care regimen of atezolizumab and bevacizumab in the first-line treatment of patients with advanced or metastatic hepatocellular carcinoma.
[Tempest Therapeutics, Inc.]